REG - Oxford Biomedica PLC - Total Voting Rights

Oxford BioMedicaAnnouncement

02/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230502:nRSB9857Xa&default-theme=true

RNS Number : 9857X  Oxford Biomedica PLC  02 May 2023

 

 

 

Oxford Biomedica

Total Voting Rights

 

 

Oxford, UK - 2 May 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica"
or "the Company"), a quality and innovation-led viral vector CDMO, today
announces that in accordance with the FCA's Disclosure Guidance and
Transparency Rule 5.6.1R, the Company's issued share capital as at the close
of business on 28 April 2023 consisted of 96,460,891 ordinary shares of 50
pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

 

Accordingly, the total number of voting rights in Oxford Biomedica plc at the
date of this notice is 96,460,891.

 

The above figure (96,460,891) may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, Oxford Biomedica
plc under the FCA's Disclosure Guidance and Transparency Rules.

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO
with a mission to enable its clients to deliver life changing therapies to
patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class
capabilities span from early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has locations across Oxfordshire, UK and a US-based subsidiary, Oxford
Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com,
www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREAESFELEDEAA